BDBM259402 US10457647, Example 1::US11180460, Example 1::US11673868, Example 1::US9512084, 1

SMILES Cc1c(NC(=O)c2ccc(cc2F)C2CC2)cc(F)cc1-c1ncnc(N)c1OC1CN(C1)C(=O)C=C

InChI Key InChIKey=OSLWRSOLKHYZCC-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 259402   

TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 4.5nMAssay Description:Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 86nMAssay Description:Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 20nMAssay Description:Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Novartis

US Patent
LigandPNGBDBM259402(US9512084, 1 | US10457647, Example 1 | US11180460,...)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
Go to US Patent